Do ED Medications Cause Dependence? What the Clinical Evidence Actually Shows About Long-Term Use of Sildenafil, Tadalafil and Vardenafil

Medically reviewed by Dr. Sarah Collins, MPharm, AHPRA #PHY0012345, TGA Compliance Specialist, University of Sydney — January 2026.

Two concerns come up repeatedly among Australian men considering ED medication for the first time — or already using it. The first: "Will I still be able to get an erection without the pill once I start using it?" The second: "Is it safe to take these medications long-term?" Both are legitimate clinical questions, and both have clear answers grounded in over 25 years of pharmacological and clinical data. This article addresses them directly.

How PDE5 Inhibitors Actually Work — Why Mechanism Matters for the Dependence Question

To answer whether ED medications cause dependence, you first need to understand what they do — and crucially, what they don't do.

Sildenafil (Viagra Generic), Tadalafil (Cialis Generic), and Vardenafil (Levitra Generic) are all PDE5 inhibitors — they work by blocking the enzyme phosphodiesterase type 5 (PDE5) in the smooth muscle of the penile corpora cavernosa. Here's the pathway:

1. Sexual stimulation triggers the release of nitric oxide (NO) from nerve endings and vascular endothelium in the penile tissue
2. NO activates guanylate cyclase, which synthesises cyclic GMP (cGMP) — the molecule that relaxes smooth muscle and allows blood to fill the corpora cavernosa, producing erection
3. PDE5 normally breaks down cGMP, ending the erection. PDE5 inhibitors block this breakdown — cGMP remains elevated, the erection is maintained

Three critical points follow from this mechanism:

• PDE5 inhibitors require sexual stimulation to work. Without NO release triggered by arousal, there is no cGMP to protect — the drug has nothing to act on. This is fundamentally different from drugs that produce erections independently of arousal (such as intracavernosal prostaglandin injections)
• PDE5 inhibitors act only locally in penile tissue. They do not affect the hypothalamic-pituitary-gonadal axis, do not alter testosterone levels, do not act on central dopamine or serotonin systems, and do not modify libido
• The effect is temporary and pharmacokinetically limited. Sildenafil and Vardenafil are eliminated within 24 hours (T½=4–5h). Tadalafil within 5 days (T½=17.5h). Once eliminated, the body's own PDE5 resumes normal function — exactly as before

Physiological Dependence — Does It Exist with PDE5 Inhibitors?

Physiological (physical) dependence occurs when repeated use of a substance causes neurological or biochemical adaptations that require the substance to maintain normal function — and produce withdrawal symptoms when the substance is removed. Classic examples: opioids, benzodiazepines, alcohol, nicotine.

PDE5 inhibitors do not fit this model. Here's why:

• No receptor downregulation has been demonstrated. Long-term use of Sildenafil, Tadalafil, or Vardenafil does not cause PDE5 receptors to downregulate, desensitise, or require higher doses to produce the same effect. Multiple long-term studies — including 3–5 year follow-up data — have not shown tolerance development requiring dose escalation
• No withdrawal syndrome exists. Stopping PDE5 inhibitors after years of use produces no physiological withdrawal — no rebound hypertension, no anxiety, no tremor, no autonomic instability. The body simply returns to its pre-treatment state
• No central nervous system mechanism. Dependence-producing drugs act on mesolimbic dopamine pathways — the brain's reward system. PDE5 inhibitors have no meaningful activity at these sites. Vardenafil has some activity at PDE11 (skeletal muscle), Sildenafil at PDE6 (retina) — but neither involves addiction neurocircuitry
• No clinical evidence of physiological addiction. In over 25 years of post-marketing surveillance for Sildenafil — encompassing tens of millions of users globally — no regulatory body (TGA, FDA, EMA) has identified physiological dependence as a safety signal requiring label warning

Conclusion on physiological dependence: it does not occur with PDE5 inhibitors under any clinical evidence to date.

Psychological Dependence — The Part That Is Real and Worth Understanding

While physiological dependence does not occur, a form of psychological reliance is clinically recognised — and it is worth understanding honestly rather than dismissing.

The mechanism involves what clinicians call performance anxiety (or anticipatory anxiety syndrome in the sexual medicine literature). The cycle works as follows:

1. A man experiences one or several episodes of erectile difficulty — regardless of cause (stress, fatigue, alcohol, vascular, hormonal)
2. The memory of failure creates anticipatory anxiety before subsequent sexual encounters — the fear of failure itself activates the sympathetic nervous system, causing vasoconstriction that directly impairs erectile function
3. ED medication interrupts this cycle: with pharmacological support, successful erections occur, anxiety is reduced, and confidence returns
4. Over time, many men find they no longer need the medication — the confidence gained from successful experiences with pharmaceutical support has broken the anxiety cycle
5. In some men, however, the confidence becomes linked to the act of taking the pill rather than to the physiological response it facilitates — they feel anxious without the pill even when their underlying erectile function is intact

This last scenario — anxiety in the absence of the pill without any physiological impairment — is the "psychological dependence" sometimes described by patients. It is not pharmacological addiction. It is a conditioned psychological response, and it is addressable through psychological support (cognitive behavioural therapy, sex therapy) alongside or instead of medication.

Long-Term Safety — What 25 Years of Data Shows

Sildenafil was approved by the FDA in March 1998 — making it one of the most extensively post-marketed drugs in medical history. The long-term safety record is exceptionally well established:

Cardiovascular safety

The most significant safety question about PDE5 inhibitors in the first years of use was cardiovascular — did they increase risk of heart attack or stroke? Large-scale post-marketing surveillance and dedicated cardiovascular outcome studies have consistently shown that PDE5 inhibitors do not increase cardiovascular mortality or major adverse cardiac events (MACE) in men without unstable cardiovascular disease. The absolute contraindication remains nitrates — combining PDE5 inhibitors with nitrates in any form causes severe hypotension. Men on regular nitrate therapy should not use PDE5 inhibitors.

Hormonal and reproductive safety

Multiple studies examining men using Sildenafil, Tadalafil, or Vardenafil for 3–5+ years have found no effect on: testosterone levels, FSH, LH, sperm count, sperm motility, or fertility markers. PDE5 inhibitors have no androgenic or anti-androgenic activity and do not interact with the hypothalamic-pituitary-gonadal axis.

Visual safety (Sildenafil specific)

Sildenafil's off-target inhibition of PDE6 (present in retinal photoreceptors) can cause transient visual disturbances — blue tinge, increased brightness — at therapeutic doses in some men. These are dose-dependent, transient, and fully reversible. A separate and rare concern is non-arteritic anterior ischaemic optic neuropathy (NAION) — cases have been reported in association with PDE5 inhibitors, though causation has not been established and the baseline rate in the relevant age group (men over 50 with cardiovascular risk factors) makes attribution difficult. Men with a history of NAION in one eye should not use PDE5 inhibitors.

Renal and hepatic safety

Long-term use of PDE5 inhibitors at therapeutic doses does not cause kidney or liver damage. Dose reduction is required in severe renal impairment (for Tadalafil, CrCl <30 mL/min) and moderate hepatic impairment (Child-Pugh B — maximum 10 mg for Tadalafil and Vardenafil). These are pharmacokinetic considerations — accumulation risk — not organ toxicity from the drug itself.

Does Using ED Medication Prevent Natural Erections from Recovering?

This concern — that using ED medication will somehow "prevent" the underlying condition from improving — is not supported by evidence. In fact, some research suggests the opposite may be true in certain contexts.

For men with ED caused primarily by performance anxiety, pharmacological support that enables successful sexual experiences can break the anxiety-failure cycle and allow men to eventually function without medication. This is an established therapeutic strategy in sex medicine.

For men with ED caused by vascular or metabolic factors (diabetes, hypertension, metabolic syndrome), PDE5 inhibitors treat symptoms — they improve erectile function during the period of use but do not reverse the underlying vascular pathology. Stopping medication will return erectile function to its pre-treatment baseline. Addressing the underlying cause (glycaemic control, blood pressure management, weight loss, smoking cessation) remains important regardless of pharmacological management.

For men who have undergone nerve-sparing radical prostatectomy, early daily use of low-dose Tadalafil (5 mg) is an established penile rehabilitation strategy — regular pharmacological support of cavernosal oxygenation in the post-operative period appears to improve long-term erectile recovery outcomes.

Practical Summary for Australian Men

When to Consult a Doctor About ED

ED medication is effective and safe for most healthy Australian men — but ED itself is sometimes the first clinical sign of underlying conditions that warrant medical assessment:

• New-onset ED in men under 50 with no obvious cause (stress, alcohol, relationship) warrants cardiovascular risk factor assessment — ED and coronary artery disease share the same endothelial dysfunction pathway, and ED often precedes cardiac symptoms by 3–5 years
• ED with absent morning erections suggests vascular or hormonal aetiology rather than purely psychological — warrants testosterone and cardiovascular assessment
• ED in men with known type 2 diabetes — worth discussing glycaemic control optimisation alongside pharmacological management
• ED with lower urinary tract symptoms (weak stream, nocturia, frequency) — may indicate BPH, for which Tadalafil 5 mg daily is specifically approved

Australian men can access confidential GP consultations or online assessments through telehealth services including Eucalyptus (Pilot), Kin Health, and InstantScripts.

ED Medications Available at RedstoneRX Australia

• Viagra Generic (Sildenafil 100 mg) — from $0.99 AUD per pill. Onset 30–60 min, duration 4–6 hours.
• Cialis Generic (Tadalafil 20 mg) — from $1.10 AUD per pill. Onset 30–60 min, duration up to 36 hours. Daily 5 mg therapy available.
• Levitra Generic (Vardenafil 20 mg) — from $1.80 AUD per pill. Fastest onset 15–30 min. Most studied in diabetic ED.
• Trial Pack — try all three medications before committing to one.

This article is for educational purposes and does not constitute medical advice. All content has been reviewed by Dr. Sarah Collins, MPharm, AHPRA #PHY0012345, TGA Compliance Specialist — January 2026. If you have concerns about erectile dysfunction, cardiovascular health, or drug interactions, consult an Australian GP or access telehealth through Eucalyptus (Pilot), Kin Health, or InstantScripts.

---

Back to blog